Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning. Read more about Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning.
Younger Children Have Increased Mixed Myeloid Chimerism with Busulfan-Based Conditioning for Hematopoietic Cell Transplantation of Non-Malignant Disease. Read more about Younger Children Have Increased Mixed Myeloid Chimerism with Busulfan-Based Conditioning for Hematopoietic Cell Transplantation of Non-Malignant Disease.
Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at Infusion. Read more about Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at Infusion.
High Exposure of Intravenous Alemtuzumab Is Associated with Increased Risk of Double-Stranded DNA Viral Infections in Patients with Non-Malignant Disease Undergoing Allogeneic HCT. Read more about High Exposure of Intravenous Alemtuzumab Is Associated with Increased Risk of Double-Stranded DNA Viral Infections in Patients with Non-Malignant Disease Undergoing Allogeneic HCT.
Fludarabine Pharmacokinetic-Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Mismatched Allogeneic Hematopoietic Cell Transplantation. Read more about Fludarabine Pharmacokinetic-Model-Based Dosing Minimizes the Risk of Graft Rejection in Pediatric Patients Undergoing Mismatched Allogeneic Hematopoietic Cell Transplantation.
A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) in Children, Adolescents and Young Adults with High-Risk T-Cell Acut Read more about A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) in Children, Adolescents and Young Adults with High-Risk T-Cell Acut
Epidemiology of Diffuse Alveolar Hemorrhage in Pediatric Allogeneic Hematopoietic Cell Transplantation Recipients. Read more about Epidemiology of Diffuse Alveolar Hemorrhage in Pediatric Allogeneic Hematopoietic Cell Transplantation Recipients.
Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia. Read more about Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia.
Cyclophosphamide and Thiotepa Increases Risk of Transplant-Associated Thrombotic Microangiopathy. Read more about Cyclophosphamide and Thiotepa Increases Risk of Transplant-Associated Thrombotic Microangiopathy.
Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols. Read more about Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols.
